NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Ibandronate

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Ibandronate is a bisphosphonate used for treatment and prevention of postmenopausal osteoporosis. Oral absorption is extremely low and is substantially reduced by food, beverages other than plain water, calcium, magnesium, iron, antacids, and vitamins, so strict fasting administration and mineral separation are essential.

Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Ibandronate is a bisphosphonate used for treatment and prevention of postmenopausal osteoporosis. NutriStack rates the supporting evidence as strong. Common adult dosing is Oral: 150 mg once monthly, taken first thing in the morning with plain water at least 60 minutes before food, drink, supplements, or other medications; older daily regimens used 2.5 mg daily. Intravenous: 3 mg every 3 months in appropriate patients., though a prescriber sets the actual dose. This profile indexes 3 sources.

What it's good for
  • Treatment of postmenopausal osteoporosis1,3
  • Prevention of postmenopausal osteoporosis1,2
  • Increased bone mineral density1,3
  • Reduced vertebral fracture risk1
What to watch for
  • Dyspepsia
  • Esophagitis
  • Esophageal ulcer
  • Esophageal abnormalities delaying emptying such as stricture or achalasia3
  • Inability to stand or sit upright for at least 60 minutes3

The bottom line

Evidence rating strong. Most-documented uses: treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, increased bone mineral density. 3 sources indexed (2004–2026), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Ibandronate binds hydroxyapatite at bone resorption surfaces and is taken up by osteoclasts during bone breakdown. As a nitrogen-containing bisphosphonate, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function and survival. Reduced osteoclast-mediated resorption increases bone mineral density and lowers vertebral fracture risk.1,3

Class
Bisphosphonate osteoporosis medication
Absorption
Best on an empty stomach
Dosing

Dosing & protocol.

Common range
Oral: 150 mg once monthly, taken first thing in the morning with plain water at least 60 minutes before food, drink, supplements, or other medications; older daily regimens used 2.5 mg daily. Intravenous: 3 mg every 3 months in appropriate patients.
Recommended form
Monthly oral tablet with strict administration instructions or supervised intravenous injection

Take oral ibandronate after an overnight fast with 6 to 8 ounces of plain water only. Remain upright and avoid food, beverages, supplements, and other medications for at least 60 minutes.

Safety

Full safety detail.

Side effects

  • Dyspepsia
  • Esophagitis
  • Esophageal ulcer
  • Abdominal pain
  • Musculoskeletal pain
  • Hypocalcemia
  • Influenza-like symptoms after IV dosing
  • Osteonecrosis of the jaw rarely
  • Atypical femur fracture with long-term use
  • Renal function concerns with IV therapy

Contraindications

  • Esophageal abnormalities delaying emptying such as stricture or achalasia3
  • Inability to stand or sit upright for at least 60 minutes3
  • Hypocalcemia3
  • Severe renal impairment3
  • Known hypersensitivity to ibandronate1,3
  • Correct calcium and vitamin D deficiency before treatment2,3
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

1
  • 1Oral ibandronate significantly reduces the risk of vertebral fractures of postmenopausal osteoporosisChesnut CH et al. · Journal of Bone and Mineral Research · 2004

    Pivotal fracture trial supports vertebral fracture reduction and bone density improvement.

Reviews & position papers

1
  • 2Clinician's Guide to Prevention and Treatment of OsteoporosisLeBoff MS et al. · Osteoporosis International · 2022

    Guideline supports bisphosphonates for high-risk patients and adequate calcium and vitamin D intake.

Reference material

1
  • 3Ibandronate Sodium Tablets US Prescribing InformationURLU.S. National Library of Medicine · DailyMed · 2026

    Labeling describes monthly fasting dosing, 60-minute upright requirement, mineral separation, hypocalcemia correction, renal limits, and esophageal warnings.

FAQ

Common questions.

Quick answers about Ibandronate, drawn from the data on this page.

What is Ibandronate?

Ibandronate is a bisphosphonate used for treatment and prevention of postmenopausal osteoporosis. Oral absorption is extremely low and is substantially reduced by food, beverages other than plain water, calcium, magnesium, iron, antacids, and vitamins, so strict fasting administration and mineral separation are essential.

What is Ibandronate used for?

Commonly cited benefits of Ibandronate include: Treatment of postmenopausal osteoporosis; Prevention of postmenopausal osteoporosis; Increased bone mineral density; Reduced vertebral fracture risk. NutriStack rates the overall evidence as strong.

What is a typical dose of Ibandronate?

A typical adult dose of Ibandronate is Oral: 150 mg once monthly, taken first thing in the morning with plain water at least 60 minutes before food, drink, supplements, or other medications; older daily regimens used 2.5 mg daily. Intravenous: 3 mg every 3 months in appropriate patients.. The commonly recommended form is Monthly oral tablet with strict administration instructions or supervised intravenous injection. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Ibandronate?

Reported side effects include dyspepsia, esophagitis, esophageal ulcer, abdominal pain, musculoskeletal pain, hypocalcemia. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Ibandronate?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Ibandronate in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.